GlassScriptPhysician profile
Maria D Martinez
NPI 1144252131
$3,078.69
in general payments reported to CMS, 2019-2025
12 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what 96% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $179 · 2021: $330 · 2022: $269 · 2023: $326 · 2024: $926 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,004 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,003.65 |
| Education | $297.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $947.36 | 2020-2025 | |
| Inspire Medical Systems, INC. | $839.63 | 2020-2025 | Inspire |
| Harmony Biosciences LLC | $411.52 | 2022-2025 | Wakix |
| Axsome Therapeutics, INC. | $215.63 | 2024-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $201.05 | 2024-2025 | Lumryz |
| Philips North America LLC | $177.10 | 2022-2025 | Patient Interface Software, (Di7) Home Pi Undivided, Dreamwear |
| Zoll Respicardia, INC. | $153.37 | 2021 | |
| Lilly USA, LLC | $31.72 | 2025 | Zepbound, Mounjaro |
| Azurity Pharmaceuticals, INC. | $29.73 | 2024 | Horizant |
| Idorsia Pharmaceuticals US INC | $28.38 | 2023 | Quviviq |
| Noctrix Health, INC. | $26.93 | 2025 | Nidra |
| Horizon Therapeutics Plc | $16.27 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.